Intravaginal DHEA, by a strictly local action, exerts beneficial effects on both vaginal atrophy symptoms and sexual dysfunction

Hormone Molecular Biology and Clinical Investigation

Volumn 4, Issue 1, 2010, Pages 499-507

  Labrie, Fernand ^a  

^a Endoceutics Inc   (Canada)

Author keywords

dehydroepiandrosterone (DHEA); intracrinology; sexual dysfunction; vaginal atrophy

Indexed keywords

ANDROGEN; ESTROGEN; PRASTERONE;

AGE; ANDROGEN BLOOD LEVEL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN BLOOD LEVEL; FEEDBACK SYSTEM; FEMALE; HUMAN; ORGASM; POSTMENOPAUSE; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; VAGINA ATROPHY; VAGINA PH; VAGINAL SECRETION;

EID: 84983224960     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.064     Document Type: Article

References (55)

1. Population Division U.S. Census Bureau. Table 1: Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007. NC-EST2007-1 May., 2008. http://www.census.gov/popest/national/asrh/NC-EST2007/NC-EST2007-01.xls.
2. Archer DF., Furst K., Tipping D., Dain MP., Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94: 498-503.
3. Christiansen C., Christensen MS., Larsen NE., Transbol IB. Patho-physiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982;55:1124-30.
4. Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33.
5. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position Statement of the North American Menopause Society. Menopause 2007; 14:357-69.
6. Barbaglia G., Macia F., Comas M., Sala M., del Mar Vernet M., Casamitjana M., Castells X. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-4.
7. Steinkellner A., Bowlin S., Denison S., Eldridge S., Lenzi L., editors. Hormone therapy prevalence rates in U.S. women 7 years after publication of the Women's Health Initiative (WHI) trial. In: NAMS 21st Annual Meeting of Transition and Change: The Future is upon us., Chicago, IL., USA. 2010; Littleton., Colorado, USA. Abstract no. P-71.
8. Labrie C., Bélanger A., Labrie F. Androgenic activity of dehy-droepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412-7.
9. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-8.
10. Labrie F., Luu-The V., Bélanger A., Lin S-X, Simard J., Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 2005; 187:169-96.
11. Luu-The V., Labrie F. The intracrine sex steroid biosynthesis pathways. In: Martini L., Chrousos GP., Labrie F., Pacak K., Pfaff De., editors. Neuroendocrinology., pathological situations and diseases. Progress in brain research. Taramani., Chennai, India: Elsevier., 2010:177-92.
12. Baxendale PM., Reed MJ., James VH. Inability of human endometrium or myometrium to aromatize androstenedione. J Steroid Biochem 1981;14:305-6.
13. Bulun SE., Lin Z., Imir G., Amin S., Demura M., Yilmaz B., Martin R., Utsunomiya H., Thung S., Gurates B., Tamura M., Langoi D., Deb S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83.
14. Toda K., Simpson ER., Mendelson CR., Shizuta Y., Kilgore MW expression of the gene encoding aromatase cytochrome P450 (CYP19) in fetal tissues. Mol Endocrinol 1994;8:210-7.
15. Labrie F., Simard J., Luu-The V., Bélanger A., Pelletier G. Structure., function and tissue-specific gene expression of 3|b-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol 1992;43:805-26.
16. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bach-varov D., Leblanc G., Durocher F., Paquet N. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131: 1571-3.
17. Labrie Y., Durocher F., Lachance Y., Turgeon C., Simard J., Labrie C., Labrie F. The human type II 17 beta-hydroxysteroid dehy-drogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol 1995;14:849-61.
18. Luu-The V., Zhang Y., Poirier D., Labrie F. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Bio-chem Mol Biol 1995;55:581-7.
19. Labrie F., Simard J., Luu-The V., Belanger A., Pelletier G., Morel Y., Mebarki F., Sanchez R., Durocher F., Turgeon C., Labrie Y., Rhéaume É, Labrie C., Lachance Y. The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson V., Levy FO., Tasken K., editors. Signal transduction in testicular cells., Ernst Schering Research Foundation Workshop. Berlin/Heidelberg: Springer-Verlag, 1996:185-218.
20. Labrie F., Luu-The V., Lin SX., Labrie C., Simard J., Breton R., Bélanger A. The key role of 17β-HSDs in sex steroid biology. Steroids 1997;62:148-58.
21. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez JL., Candas B., Castiel I., Chaussade V., Deloche C., Leclaire J. Androgen glucuronides., instead of testosterone., as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182-8.
22. Labrie F., Cusan L., Gomez JL., Martel C., Bérubé R., Bélanger P., Chaussade V., Deloche C., Leclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1-9.
23. Labrie F., Cusan L., Gomez JL., Martel C., Bérubé R., Bélanger P., Bélanger A., Vandenput L., Mellström D., Ohlsson C. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009; 113:52-6.
24. Rossouw JE., Anderson GL., Prentice RL., LaCroix AZ., Koo-perberg C., Stefanick ML., Jackson RD., Beresford SA., Howard BV., Johnson KC., Kotchen JM., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
25. Beral V. Breast cancer and hormone-replacement therapy in the Million Women study. Lancet 2003;362:419-27.
26. Beral V., Bull D., Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women study. Lancet 2005;365:1543-51.
27. Riman T., Dickman PW., Nilsson S., Correia N., Nordlinder H., Magnusson CM., Weiderpass E., Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
28. Grodstein F., Manson JE., Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15: 35-44.
29. Hsia J., Langer RD., Manson JE., Kuller L., Johnson KC., Hendrix SL., Pettinger M., Heckbert SR., Greep N., Crawford S., Eaton CB., Kostis JB., Caralis P., Prentice R. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65.
30. Pines A., Sturdee DW., MacLennan AH., Schneider HP., Burger H., Fenton A. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007;10:267-9.
31. Ruttimann J. The menopause brain effect: Can hormone therapy help? Endocr News 2008:15-6.
32. Labrie F., Martel C., Balser J. Wide distribution of the serum DHEA and sex steroids levels in postmenopausal women-role of the ovary? Menopause 2011;Epub ahead of print.
33. Fogle RH., Stanczyk FZ., Zhang X., Paulson RJ. Ovarian andro-gen production in postmenopausal women. J Clin Endocrinol Metab 2007;92:3040-3.
34. Spark R. F. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril 2002;77(Suppl 4):S19-25.
35. Longcope C., Franz C., Morello C., Baker R., Johnston CC Jr. Steroid and gonadotropin levels in women during the peri-men-opausal years. Maturitas 1986;8:189-96.
36. Zumoff B., Strain GW., Miller LK., Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80:1429-30.
37. Havelock JC., Rainey WE., Bradshaw KD., Carr BR. The post-menopausal ovary displays a unique pattern of steroidogenic enzyme expression. Hum Reprod 2006;21:309-17.
38. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., Lin S-X, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of andro-gens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
39. Labrie F., Belanger A., Cusan L., Gomez JL., Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402.
40. Coleman DL., Leiter EH., Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982;31:830-3.
41. Tchernof A., Despres JP., Belanger A., Dupont A., Prud'homme D., Moorjani S., Lupien PJ., Labrie F. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 1995; 44:513-9.
42. Simon JA. Vulvovaginal atrophy: new and upcoming approaches. Menopause 2009;16:5-7.
43. Diamond P., Cusan L., Gomez JL., Bélanger A., Labrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol 1996;150: S43-50.
44. Labrie F., Diamond P., Cusan L., Gomez JL., Belanger A., Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone., vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-505.
45. Labrie F. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3:584-93.
46. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez JL., Girard G., Baron M., Ayotte N., Moreau M., Dubé R., Côté I., Labrie C., Lavoie L., Berger L., Gilbert L., Martel C., Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22.
47. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez JL., Girard G., Baron M., Ayotte N., Moreau M., Dubé R., Côté I., Labrie C., Lavoie L., Berger L., Gilbert L., Martel C., Balser J. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-31.
48. Buster JE. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT). Menopause 2009;16:858-9.
49. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez JL., Girard G., Baron M., Ayotte N., Moreau M., Dubé R., Côté I., Labrie C., Lavoie L., Berger L., Gilbert L., Martel C., Balser J. Serum steroid levels during 12-week intravaginal dehydro-epiandrosterone administration. Menopause 2009;16:897-906.
50. Labrie F., Cusan L., Gomez JL., Côté I., Bérubé R., Bélanger P., Martel C., Labrie C. Corrigendum to: effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in post-menopausal women. J Steroid Biochem Mol Biol 2008;112: 169.
51. Labrie F., Cusan L., Gomez JL., Côté I., Bérubé R., Bélanger P., Martel C., Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-94.
52. Labrie F., Cusan L., Gomez JL., Côté I., Bérubé R., Bélanger P., Martel C., Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmeno-pausal women. Menopause 2009;16:30-6.
53. Labrie F. DHEA after menopause-sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Manag 2010;19:14-24.
54. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez J., Candas B., Chaussade V., Castiel I., Deloche C., Leclaire J. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007;103:178-88.
55. Labrie F. DHEA., important source of sex steroids in men and even more in women. In: Martini L., Chrousos GP., Labrie F., Pacak, editors. Neuroendocrinology. The Normal Neuroendo-crine System., Progress in Brain Research. Elsevier., 2010:97-148.